Analysts Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Price Target at $51.60

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have been given a consensus recommendation of “Buy” by the seven brokerages that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $51.60.

TARS has been the topic of several research analyst reports. William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Oppenheimer restated an “outperform” rating and set a $63.00 target price (up previously from $61.00) on shares of Tarsus Pharmaceuticals in a research report on Friday, August 9th.

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock opened at $49.42 on Monday. Tarsus Pharmaceuticals has a 12 month low of $15.47 and a 12 month high of $51.59. The company has a current ratio of 7.03, a quick ratio of 6.99 and a debt-to-equity ratio of 0.28. The business’s 50 day simple moving average is $35.95 and its 200 day simple moving average is $32.00. The company has a market cap of $1.88 billion, a price-to-earnings ratio of -11.03 and a beta of 1.00.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($0.98) by $0.10. Tarsus Pharmaceuticals had a negative return on equity of 63.99% and a negative net margin of 180.00%. The business had revenue of $40.81 million for the quarter, compared to the consensus estimate of $31.30 million. During the same quarter in the prior year, the business earned ($1.17) earnings per share. Sell-side analysts forecast that Tarsus Pharmaceuticals will post -3.71 EPS for the current year.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several institutional investors have recently made changes to their positions in TARS. Quest Partners LLC bought a new position in shares of Tarsus Pharmaceuticals in the second quarter worth $61,000. Canada Pension Plan Investment Board bought a new position in Tarsus Pharmaceuticals in the second quarter valued at $114,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Tarsus Pharmaceuticals by 33.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock valued at $166,000 after acquiring an additional 1,530 shares during the last quarter. Dark Forest Capital Management LP bought a new position in Tarsus Pharmaceuticals in the second quarter valued at $202,000. Finally, Bleakley Financial Group LLC bought a new position in Tarsus Pharmaceuticals in the first quarter valued at $223,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.